1 |
CDK4
| 11件: p53 signaling pathway p53 signaling pathway, PI3K-Akt signaling pathway, Tight junction, T cell receptor signaling pathway, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer | D10688
D10688
|
Abemaciclib
| 1件: 34 34 |
2 |
CDK6
| 10件: p53 signaling pathway p53 signaling pathway, PI3K-Akt signaling pathway, Measles, Pathways in cancer, Viral carcinogenesis, MicroRNAs in cancer, Pancreatic cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer | D10688
D10688
|
Abemaciclib
| 1件: 34 34 |
3 |
IFNA1
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
4 |
IFNA1
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
5 |
IFNA2
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
6 |
IFNA2
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
7 |
IFNA4
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
8 |
IFNA4
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
9 |
IFNA5
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
10 |
IFNA5
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
11 |
IFNA6
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
12 |
IFNA6
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
13 |
IFNA7
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
14 |
IFNA7
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
15 |
IFNA8
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
16 |
IFNA8
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
17 |
IFNA10
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
18 |
IFNA10
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
19 |
IFNA13
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
20 |
IFNA13
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
21 |
IFNA14
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
22 |
IFNA14
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
23 |
IFNA16
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
24 |
IFNA16
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
25 |
IFNA17
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
26 |
IFNA17
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
27 |
IFNA21
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
28 |
IFNA21
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
29 |
IFNAR1
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D00745
D00745
|
Interferon alfa-2a
| 1件: 56 56 |
30 |
IFNAR1
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D00746
D00746
|
Interferon beta-1b
| 1件: 13 13 |
31 |
IFNAR1
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D02745
D02745
|
Interferon alfa-2b
| 2件: 25 25, 34 |
32 |
IFNAR1
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D03305
D03305
|
Interferon alfa
| 6件: 13 13, 25, 26, 28, 56, 96 |
33 |
IFNAR1
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| 4件: 13 13, 26, 96, 97 |
34 |
IFNAR1
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D10483
D10483
|
Peginterferon beta-1a
| 1件: 13 13 |
35 |
IFNAR1
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D11082
D11082
|
Anifrolumab
| 3件: 46 46, 49, 53 |
36 |
IFNAR2
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D00745
D00745
|
Interferon alfa-2a
| 1件: 56 56 |
37 |
IFNAR2
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D00746
D00746
|
Interferon beta-1b
| 1件: 13 13 |
38 |
IFNAR2
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D02745
D02745
|
Interferon alfa-2b
| 2件: 25 25, 34 |
39 |
IFNAR2
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D03305
D03305
|
Interferon alfa
| 6件: 13 13, 25, 26, 28, 56, 96 |
40 |
IFNAR2
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| 4件: 13 13, 26, 96, 97 |
41 |
IFNAR2
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D10483
D10483
|
Peginterferon beta-1a
| 1件: 13 13 |
42 |
IFNAR2
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer | D11082
D11082
|
Anifrolumab
| 3件: 46 46, 49, 53 |
43 |
IL1A
| 10件: Necroptosis Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Measles, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
44 |
IL1A
| 10件: Necroptosis Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Measles, Rheumatoid arthritis | D06635
D06635
|
Rilonacept
| 4件: 51 51, 106, 107, 266 |
45 |
IL1A
| 10件: Necroptosis Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Measles, Rheumatoid arthritis | D11253
D11253
|
Bermekimab
| 1件: 51 51 |
46 |
IL1B
| 19件: NF-kappa B signaling pathway NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
47 |
IL1B
| 19件: NF-kappa B signaling pathway NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Rheumatoid arthritis | D06635
D06635
|
Rilonacept
| 4件: 51 51, 106, 107, 266 |
48 |
IL1B
| 19件: NF-kappa B signaling pathway NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Rheumatoid arthritis | D09315
D09315
|
Canakinumab
| 10件: 46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 |
49 |
IL1B
| 19件: NF-kappa B signaling pathway NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Rheumatoid arthritis | D09911
D09911
|
Gevokizumab
| 4件: 41 41, 50, 56, 269 |
50 |
IL2RA
| 6件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer | D00748
D00748
|
Aldesleukin
| 6件: 2 2, 35, 49, 65, 96, 97 |
51 |
IL2RA
| 6件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer | D03058
D03058
|
Basiliximab
| 6件: 2 2, 50, 66, 97, 222, 228 |
52 |
IL2RA
| 6件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer | D03639
D03639
|
Daclizumab
| 8件: 13 13, 56, 60, 65, 97, 107, 283, 284 |
53 |
IL2RB
| 7件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Transcriptional misregulation in cancer | D00748
D00748
|
Aldesleukin
| 6件: 2 2, 35, 49, 65, 96, 97 |
54 |
IL2RG
| 7件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Primary immunodeficiency | D00748
D00748
|
Aldesleukin
| 6件: 2 2, 35, 49, 65, 96, 97 |
55 |
IL6
| 18件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
56 |
IL6
| 18件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D08976
D08976
|
Pomalidomide
| 5件: 28 28, 51, 85, 227, 331 |
57 |
IL6
| 18件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D09669
D09669
|
Siltuximab
| 2件: 28 28, 331 |
58 |
IL6
| 18件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D10080
D10080
|
Sirukumab
| 2件: 41 41, 46 |
59 |
IL6
| 18件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D12487
D12487
|
Olokizumab
| 2件: 46 46, 96 |
60 |
IL12A
| 9件: Toll-like receptor signaling pathway Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer | D09214
D09214
|
Ustekinumab
| 16件: 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
61 |
IL12B
| 10件: Toll-like receptor signaling pathway Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Proteoglycans in cancer | D09214
D09214
|
Ustekinumab
| 16件: 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
62 |
JAK1
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09959
D09959
|
Ruxolitinib
| 3件: 60 60, 65, 228 |
63 |
JAK1
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
64 |
JAK1
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10308
D10308
|
Baricitinib
| 13件: 2 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 |
65 |
JAK1
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10653
D10653
|
Peficitinib
| 1件: 46 46 |
66 |
JAK1
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10871
D10871
|
Filgotinib
| 6件: 46 46, 53, 96, 97, 222, 271 |
67 |
JAK1
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10944
D10944
|
Itacitinib
| 4件: 46 46, 51, 97, 228 |
68 |
JAK1
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10994
D10994
|
Upadacitinib
| 8件: 40 40, 41, 46, 49, 96, 97, 107, 271 |
69 |
JAK1
| 14件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11400
D11400
|
Abrocitinib
| 1件: 84 84 |
70 |
JAK3
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
71 |
JAK3
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency | D10653
D10653
|
Peficitinib
| 1件: 46 46 |
72 |
NFKB1
| 34件: Ras signaling pathway Ras signaling pathway, NF-kappa B signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D01146
D01146
|
Iguratimod
| 5件: 46 46, 51, 53, 271, 300 |
73 |
TLR7
| 3件: Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Measles | D02500
D02500
|
Imiquimod
| 2件: 34 34, 51 |
74 |
PIK3CA
| 44件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11011
D11011
|
Alpelisib
| 1件: 138 138 |
75 |
PIK3CA
| 44件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
76 |
PIK3CB
| 44件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
77 |
PIK3CD
| 44件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
78 |
PIK3CD
| 44件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11437
D11437
|
Parsaclisib
| 3件: 35 35, 53, 61 |
79 |
TLR9
| 5件: Toll-like receptor signaling pathway Toll-like receptor signaling pathway, Salmonella infection, Tuberculosis, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer | D12275
D12275
|
Cobitolimod
| 1件: 97 97 |
80 |
BCL2
| 20件: Platinum drug resistance Platinum drug resistance, NF-kappa B signaling pathway, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, Necroptosis, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Small cell lung cancer | D10679
D10679
|
Venetoclax
| 1件: 28 28 |
81 |
RELA
| 34件: Ras signaling pathway Ras signaling pathway, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Mitophagy - animal, PI3K-Akt signaling pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D12181
D12181
|
Edasalonexent
| 1件: 113 113 |
82 |
TYK2
| 7件: Necroptosis Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Measles | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
83 |
TYK2
| 7件: Necroptosis Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Measles | D11817
D11817
|
Deucravacitinib
| 3件: 49 49, 96, 97 |
84 |
CASP9
| 18件: Platinum drug resistance Platinum drug resistance, p53 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Thyroid hormone signaling pathway, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, Viral myocarditis | D11195
D11195
|
Rimiducid
| 6件: 19 19, 60, 65, 284, 285, 326 |
85 |
CD3D
| 6件: Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06314
D06314
|
Visilizumab
| 2件: 96 96, 97 |
86 |
CD3D
| 6件: Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D08959
D08959
|
Otelixizumab
| 1件: 46 46 |
87 |
CD3E
| 6件: Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06314
D06314
|
Visilizumab
| 2件: 96 96, 97 |
88 |
CD3E
| 6件: Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D08959
D08959
|
Otelixizumab
| 1件: 46 46 |
89 |
CD3E
| 6件: Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D11463
D11463
|
Mosunetuzumab
| 1件: 49 49 |
90 |
CD3G
| 5件: Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer | D06314
D06314
|
Visilizumab
| 2件: 96 96, 97 |
91 |
CD3G
| 5件: Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08959
D08959
|
Otelixizumab
| 1件: 46 46 |